COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

Micro-Scaled Method Holds Promise as Improved Cancer Diagnostic Platform

Using a single-needle biopsy and new technology for tumor diagnosis developed by Baylor College of Medicine and the Broad Institute of MIT and Harvard, researchers have been able to provide a more detailed and wider window into cancer biology, tumor type and the mechanisms of response and resistance to therapy than with conventional approaches.


GDC Release 22 Has GBM Discovery Data

The Genomic Data Commons (GDC) data release 22 is now available and includes data from the CPTAC Glioblastoma Multiforme Discovery Study. 


Request For Proposal - Biospecimen Core Resource

The Clinical Proteomic Tumor Analysis Consortium (CPTAC), sponsored by the National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research (OCCPR) and managed by The Frederick National Laboratory for Cancer Research (FNLCR), is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteomics, genomics and proteogenomics.  


GBM Discovery Data Available on the PDC

Glioblastoma Multiforme Discovery Study proteomic and phosphoproteomic data previously available only on thte CPTAC Data Portal is now available on the Proteomic Data Commons.  


CPTAC Radiology Data Release Through TCIA

TCIA has released its quarterly update for CPTAC radiology data with 44 new radiology cases!  These cases span cutaneous melanoma, glioblastoma multiforme, head & neck squamous cell carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, pancreatic ductal adenocarcinoma and sarcoma tumor tissue types.  In addition, the TCIA monthly histopathology report lists the addition of 10 new pathology slides


OCCPR Webinar: NCI's Antibody Program

Antibodies are among the most commonly used tools in the biological sciences - put to work in many experiments to identify and isolate other molecules.  NCI’s Antibody Program has developed more than 500 available antibodies that have been designed and optimized, with the vast majority developed as fit-for-purpose reagents.


CPTAC Glioblastoma Multiforme (GBM) Discovery Study Data Release

Proteomic and phosphoproteomic data for the CPTAC Glioblastoma Discovery Study is now available on the CPTAC Data Portal. 


Even More CPTAC Pathology Images Available!

...And there's more!!!  Another new batch of CPTAC histopathology imaging data has been released and is now publicly available on the TCIA CPTAC Pathology Portal.


CPTAC Researchers Associate High Immune Checkpoint Components and Immune Tolerance with Poor Clinical Outcomes in Luminal B Breast Cancer

As part of NIH’s mission for collaboration and team science, Dr. Matthew Ellis, Co-Principal Investigator of the CPTAC Proteogenomic Translational Research Center and Dr.


OCCPR Webinar: Proteomic Assay Portal

Did you know about NCI’s Proteomic (CPTAC) Assay Portal?  It’s a free resource for biological scientists performing mass spectroscopy.  The portal houses more than 2300 fit-for-purpose, proteomic assays designed and optimized for anyone to use.   Each assay is validated using CPTAC experimental g


Pages